SIP
CYTK icon

Stoneridge Investment Partners’s Cytokinetics CYTK Stock Holding History

Stoneridge Investment Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-15,655
Closed -$149K – 276
2016
Q2 		$149K Hold
15,655
– – 0.02% 270
2016
Q1 		$110K Sell
15,655
-5,931
-27% -$43.3K 0.02% 281
2015
Q4 		$226K Sell
21,586
-66,340
-75% -$651K 0.03% 257
2015
Q3 		$588K Sell
87,926
-1,250
-1% -$8.53K 0.08% 196
2015
Q2 		$599K Buy
89,176
+25,869
+41% +$170K 0.07% 192
2015
Q1 		$429K Buy
63,307
+1,921
+3% +$14.3K 0.05% 217
2014
Q4 		$492K Buy
61,386
+13,245
+28% +$56.8K 0.06% 188
2014
Q3 		$169K Hold
48,141
– – 0.03% 230
2014
Q2 		$230K Buy
48,141
+13,167
+38% +$80.4K 0.03% 204
2014
Q1 		$332K Sell
34,974
-800
-2% -$7.24K 0.06% 152
2013
Q4 		$233K Buy
+35,774
New +$235K 0.04% 176

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Stoneridge Investment Partners's CYTK Position: Q3 2016 in Review

Stoneridge Investment Partners sold out of Cytokinetics (CYTK) in Q3 2016, closing a stake of 15,655 shares — an estimated $149K sold.

Stoneridge Investment Partners first reported a position in CYTK in Q4 2013 and held it in 11 quarters. The position peaked at $599K in Q2 2015. 91 funds tracked by Wall St. Rank hold CYTK as of Q3 2016.

  • Stoneridge Investment Partners reported no remaining Cytokinetics position as of Q3 2016 after selling out during the quarter.
  • Stoneridge Investment Partners sold 15,655 Cytokinetics shares in Q3 2016, an estimated $149K.
  • Stoneridge Investment Partners first reported a position in Cytokinetics in Q4 2013 and held it in 11 quarters.
  • Stoneridge Investment Partners's Cytokinetics position peaked at $599K in Q2 2015.
  • 91 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2016.

Based on Stoneridge Investment Partners's 13F filing for Q3 2016, filed 28 Oct 2016.